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A 67-year-old male patient with stable an-
gina, hypertension and hypercholesterolemia who 
underwent bare metal stent (BMS) implantation 
in the distal right coronary artery (RCA) (Azule 
3 × 9 mm) and everolimus-eluting stent (EES) im-
plantation in the first diagonal branch (D1) (Xience 
2.25 × 18 mm) and in the proximal circumflex 
branch (LCx) (Xience 3 × 28 mm). One year subse-
quent to the precedure the patient was readmitted 
for relapse of the angina Canadian Cardiovascular 
Society scale II, exhibiting a positive exercise test. 
The coronary angiography showed a distal-edge 
in-stent restenosis (ISR) in the distal RCA, ex-
tending to the posterior descending artery (PDA), 
Medina 110 bifurcation (Fig. 1A). Optical coherence 
tomography (OCT) showed predominantly fibroli-
pidic restenotic tissue, with minimal lumen area 
(MLA) 1.95 mm2, minimal lumen diameter (MLD) 
1.57 mm, proximal reference vessel diameter 
(RVD) 3.1 mm, distal RVD 2.75 mm and lesion 
length 21.2 mm (Fig. 1B, C). 
Optical coherence tomography-guided im-
plantation of a bioresorbable scaffold (BRS) to 
treat the bifurcation ISR was performed through 
a radial approach, using a 6 french guiding-catheter. 
Guidewires were placed in the PDA and in the 
posterolateral artery (PLA), in order to protect 
the side branch in case of an eventual occlusion. 
Predilation 1:1 with a non-compliant (NC) balloon 
3.0 × 18 mm (16 atm) was performed until the 
balloon was completely expanded in angiography. 
A second OCT run verified fragmentation of rest-
enotic tissue and sufficient luminal gain to ensure 
adequate scaffold expansion. A poly-lactide BRS 
(ABSORB 3 × 28 mm) was then slowly deployed 
at 12 atm, holding pressure for 60 s. Proximal-
optimalization-technique with an NC-balloon 
3.25 × 15 mm (16 atm) was then performed by 
placing the proximal edge of the distal marker of 
the balloon at the carina of the PDA-PLA bifurca-
tion, with an optimal angiographic result (Fig. 1D). 
A final OCT pullback showed optimal apposi-
tion and expansion (MLA 5.3 mm2/MLD 2.6 mm; 
Fig. 1E), structural integrity of the device and 
clear access to the PLA side branch through the 
scaffold struts (Fig. 1F). Three-month follow-up 
documented an optimal clinical and angiographical 
result (Suppl. Video 1).
Poly-lactide BRS are supposed to resorb com-
pletely [1–5], depending on the specific device and 
on patient/local conditions. The resorption restores 
vasomotion and eventually normal endothelial 
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function [2, 6, 7]. Moreover, the disappearance 
of a permanent foreign body in the vessel wall is 
also intended to minimize inflammation and risk 
of device failure, i.e. very late BRS-thrombosis, 
neoatherosclerosis, restenosis and catch-up phe-
nomenon. Nonetheless, the suitability of poly-
lactide BRS for bifurcations is currently a matter 
of debate, with reported higher risks of side branch 
occlusion [8] and of scaffold rupture following some 
bifurcation techniques [9, 10]. Some scientific re-
ports however, focus on dedicating interventional 
techniques to minimize these risks [10, 11]. ISR 
is also a challenging scenario for BRS, because the 
expansion of the scaffold is sensibly inferior than 
in on-label indications [12] and reported clinical 
outcomes are inconsistent to date [13, 14]. The 
current case reports the successful treatment of 
a lesion combining both bifurcation and ISR chal-
lenges, by implanting a BRS. OCT-guidance played 
an instrumental role in achieving an optimal result 
and it may be considered for all off-label indications 
of BRS devices.
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artery; PLA — posterolateral artery.
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